CN115666626A - 一种治疗阿尔茨海默病的方法和药物 - Google Patents

一种治疗阿尔茨海默病的方法和药物 Download PDF

Info

Publication number
CN115666626A
CN115666626A CN202180023646.XA CN202180023646A CN115666626A CN 115666626 A CN115666626 A CN 115666626A CN 202180023646 A CN202180023646 A CN 202180023646A CN 115666626 A CN115666626 A CN 115666626A
Authority
CN
China
Prior art keywords
plasminogen
group
mice
plasmin
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180023646.XA
Other languages
English (en)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tailunji International Co ltd
Original Assignee
Tailunji International Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tailunji International Co ltd filed Critical Tailunji International Co ltd
Publication of CN115666626A publication Critical patent/CN115666626A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了一种预防和治疗阿尔茨海默病的方法和药物，包括给药受试者治疗有效量的纤维蛋白溶酶原激活途径组分。本发明还提供了包含纤维蛋白溶酶原激活途径组分的药物、药物组合物、制品、试剂盒。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202180023646.XA 2020-03-24 2021-03-24 一种治疗阿尔茨海默病的方法和药物 Pending CN115666626A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020102134627 2020-03-24
CN202010213462 2020-03-24
PCT/CN2021/082701 WO2021190558A1 (zh) 2020-03-24 2021-03-24 一种治疗阿尔茨海默病的方法和药物

Publications (1)

Publication Number Publication Date
CN115666626A true CN115666626A (zh) 2023-01-31

Family

ID=77890658

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180023646.XA Pending CN115666626A (zh) 2020-03-24 2021-03-24 一种治疗阿尔茨海默病的方法和药物

Country Status (8)

Country Link
US (1) US20230173039A1 (zh)
EP (1) EP4122488A4 (zh)
JP (1) JP2023518504A (zh)
KR (1) KR20220156927A (zh)
CN (1) CN115666626A (zh)
CA (1) CA3176926A1 (zh)
TW (2) TW202342093A (zh)
WO (1) WO2021190558A1 (zh)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US6136548A (en) * 1994-11-22 2000-10-24 Rutgers, The State University Of New Jersey Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging
JPH11510170A (ja) 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
AU3173301A (en) * 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
EP1130031A1 (en) * 2000-02-25 2001-09-05 Universitair Medisch Centrum Utrecht Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
EP1485709A4 (en) * 2002-02-19 2005-09-21 Univ Vanderbilt THERAPIES OF PAI-1 INHIBITORS AND NON-HUMAN TRANSGENIC ANIMALS FOR THE SYSTEMATIC RESEARCH OF PAI-1 INHIBITING CANDIDATES
US20060104969A1 (en) * 2004-08-16 2006-05-18 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
CN102154253A (zh) * 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
DE102011003944A1 (de) * 2011-02-10 2012-08-16 Oxprotect Gmbh Detektion und Entfernung von missgefalteten Proteinen/Peptiden
US20140186423A1 (en) * 2012-03-27 2014-07-03 Mathew Gelfand Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease
TWI746581B (zh) * 2016-12-15 2021-11-21 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防和治療脂質腎損傷之藥劑上的用途
CN109125715A (zh) * 2017-06-19 2019-01-04 深圳瑞健生命科学研究院有限公司 一种调控glp-1/glp-1r的方法和药物
CN111344004A (zh) * 2017-06-19 2020-06-26 泰伦基国际有限公司 一种调控glp-1/glp-1r 的方法和药物
TW201904990A (zh) * 2017-06-23 2019-02-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
TWI763960B (zh) * 2017-12-15 2022-05-11 大陸商深圳瑞健生命科學研究院有限公司 一種預防或治療骨關節炎的方法及藥物
WO2022105788A1 (zh) * 2020-11-17 2022-05-27 泰伦基国际有限公司 一种提高bdnf水平的方法和药物

Also Published As

Publication number Publication date
EP4122488A4 (en) 2023-04-05
TW202144001A (zh) 2021-12-01
TW202342093A (zh) 2023-11-01
US20230173039A1 (en) 2023-06-08
JP2023518504A (ja) 2023-05-01
WO2021190558A1 (zh) 2021-09-30
EP4122488A1 (en) 2023-01-25
KR20220156927A (ko) 2022-11-28
CA3176926A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
US20240000903A1 (en) Method and drug for increasing bdnf level
TWI830088B (zh) 一種提高ngf水平的方法和藥物
TWI787732B (zh) 一種預防和治療多發性硬化症的方法和藥物
TWI787767B (zh) 一種治療亨廷頓病的方法和藥物
US20230066726A1 (en) Method for treatment of nerve injury and related disease
WO2021190561A1 (zh) 一种治疗帕金森病的方法和药物
CN115666626A (zh) 一种治疗阿尔茨海默病的方法和药物
CN115666625A (zh) 一种促进错误折叠蛋白及其聚集物降解的方法和药物
EP3967322A1 (en) Method and medicine for treating amyotrophic lateral sclerosis
US20230181699A1 (en) Method and drug for treating spinal muscular atrophy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination